Although myeloma is, like leukemias and lymphomas, a cancer involving white blood cells known as lymphocytes, myeloma cells don't traditionally express CD19 on their surface because they arise from the most mature type of lymphocytes — plasma cells.
Not exact matches
An update search enlarged the pool of study data, but
did not change the content of the conclusion of the benefit assessment of stem
cell transplantation (SCT) for multiple
myeloma conducted in 2012.
«Stem
cell transplantation for multiple
myeloma: New data
did not change conclusion.»
The idea is to use the understanding of the pathways that adiponectin uses to kill
myeloma cells to create a drug that would
do the same thing.
«When the multiple
myeloma cells come to the new bone sites, the bone immune
cells think, «This is one of our neighbor
cells,» and therefore
do not eliminate them.
Do Plasma
Cells Affect Hemoglobin and Red Blood
Cell Counts in Patients With and Without
Myeloma?
No Association Between Response Rates and Survival in Newly Diagnosed Multiple
Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who d
Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple
myeloma in populations of patients who received stem cell transplant and those who d
myeloma in populations of patients who received stem
cell transplant and those who
did not.
Inspired by XBP - 1's roles in maintaining a homeostatic ER, the lab began to examine the role of XBP - 1 in B -
cell leukemia whose progression
does not require dramatic ER expansion like that in multiple
myeloma.